Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis

Abstract

Prolactin (PRL) has been involved in the pathogenesis of systemic lupus erythematosus (SLE) and hyperprolactinemia has been connected with systemic activity. However, the clinical significance of PRL has not been investigated in lupus glomerulonephritis (GN). Methods: We studied SLE patients (ACR criteria) with biopsy-proven renal disease. Renal histology was classified according to World Health Organization (WHO) criteria. Renal function tests, albuminuria, complement levels (nephelometry), anti-DNA antibodies (C. luciliae) and serum and urine PRL concentrations (RIA) were determined at baseline and at 4-month intervals for one year. Renal activity was defined as mild, moderate or severe according to serum creatinine, creatinine clearance, albuminuria, red blood cells (RBC), and casts. Results: There were 26 patients with mean age 28.5 y and mean disease duration 47.9 months. Twenty patients had diffuse proliferative glomerulonephritis (GN), four had focal GN and two had membranous GN with proliferative changes. Renal activity was mild in ten patients, moderate in ten and severe in six. Mean serum (24.7 5.3) and urine (0.90 0.36) PRL levels were higher in patients with severe renal activity (P < 0.05 compared with mild group). PRL levels decreased after treatment, but this trend was not uniform during the follow-up period. Conclusion: Hyperprolactinemia was prevalent in SLE patients and high levels of PRL in the serum and urine could be related to severe renal disease.

Keywords

prolactin glomerulonephritis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Besedosvsky HO , Del Rey A . Immuno-neuro-endocrine interactions: facts and hypothesis. Endocr Rev 1996; 64-102.

Berczi Y , Nagy E . The effect of prolactin and growth hormone on hemolymphopoietic tissue and immune function. In: Berczi Y , Kovacs K (eds) Hormones and immunity MTP Press: Lancaster 1987; p 145-145.

Buskila D , Sukrenik S , Shoenfeld Y . The possible role of prolactin in autoimmunity . Am J Reprod Immunol 1991; 26: 118-123 .

Walker SE , Allen SH , Hoffman, RW , McMurray RW . Prolactin: a stimulator of disease activity in systemic lupus erythematosus . Lupus 1995; 4: 3-9 .

Jara-Quezada L , Graef A , Lavalle C . Prolactin and hormones during pregnancy in systemic lupus erythematosus . J Rheumatol 1991; 18: 349-353 .

Jara LJ et al. Hyperprolactinemia in systemic lupus erythematosus (SLE): association with disease activity . Am J Med Sci 1992; 303: 222-226 .

Neidhart M . Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune process in systemic lupus erythematosus and other connective tissue diseases . J Rheumatol 1996; 23: 476-481 .

Buskila D et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus . J Rheumatolo 1996; 23: 269-272 .

Pauzner R et al. Prolactin in systemic lupus erythematosus . J Rheumatol 1994; 21: 2064-2067 .

10.

McMurray R et al. Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 3780-3787 .

11.

McMurray R et al. Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone . Clin Immunol Immunopathol 1994; 71: 1143-1151 .

12.

Russel DH et al. Prolactin receptors on human T and B lymphocytes; antagonism of prolactin binding by cyclosporine . J Immunol 1985; 134: 3027-3031 .

13.

Houghe R , Delhase M , Vezgani P . Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system . Immunol Today 1993; 14: 212-214 .

14.

Larrea F et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus . J Clin Endocrinol Metabol 1997; 82: 3664-3669 .

15.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

16.

Appel GB et al. Renal involvement in systemic lupus erythematosus: A study of 56 patients emphasizing histologic classification . Medicine 1983; 75: 382-389 .

17.

Austin HA et al. Prognostic factors in lupus nephritis: contribution of renal histopathologic data . Am J Med 1983; 75: 383-388 .

18.

Iwano M et al. Urinary levels of IL-6 in patients with active lupus nephritis . Clin Nephrology 1993; 40: 16-21 .

19.

Spangelo BN , Hall N , Ross PC , Goldstein A . Stimulation of in vivo antibody production and concanavalin-A-induced mouse spleen cells mitogenesis by prolactin . Immunopharmacology 1987; 14: 11-20 .

20.

McMurray RW , Hoffman R , Walker SE . In vivo prolactin manipulations alters in vitro IL-2, IL-4, and IFN mRNA levels in female B/W mice (abstr) . Clin Res 1991; 39: p 734-734 .

21.

Gutierrez ME et al. Prolactin-induced immunoglobulin and autoanti-body production by peripheral blood monouclear cells from systemic lupus erythematosus and normal individuals . Int Arch Allergy Immunol 1996; 109: 229-235 .

22.

Gutiérrez MA et al. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity . Lupus 1995; 4: 348-352 .

23.

Jara LJ et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998 (in press).